Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102)

Siegel, 2017, Cancer statistics, 2017, CA Cancer J Clin, 67, 7, 10.3322/caac.21387 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon Cancer. Version 1.2017. Available at: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed: February 16, 2017. Grothey, 2013, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 381, 303, 10.1016/S0140-6736(12)61900-X 2015 Emura, 2005, Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo, Int J Oncol, 27, 449 Temmink, 2007, Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies, Cancer Sci, 98, 779, 10.1111/j.1349-7006.2007.00477.x Longley, 2003, 5-Fluorouracil: mechanisms of action and clinical strategies, Nat Rev Cancer, 3, 330, 10.1038/nrc1074 Wilson, 2014, Standing the test of time: targeting thymidylate biosynthesis in cancer therapy, Nat Rev Clin Oncol, 11, 282, 10.1038/nrclinonc.2014.51 Longo-Muñoz, 2017, Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial, Clin Transl Oncol, 19, 227, 10.1007/s12094-016-1528-7 Mayer, 2015, Randomized trial of TAS-102 for refractory metastatic colorectal cancer, N Engl J Med, 372, 1909, 10.1056/NEJMoa1414325 2015 2016 Shitara, 2011, Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy, Cancer Chemother Pharmacol, 68, 301, 10.1007/s00280-010-1487-6 Yamanaka, 2007, Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma, Br J Cancer, 97, 37, 10.1038/sj.bjc.6603831 Soveria, 2014, Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: is efficacy an impact of toxicity?, Eur J Cancer, 50, 2966, 10.1016/j.ejca.2014.08.017 Sunaga, 2014, The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy, Eur J Cancer Care (Engl), 23, 394, 10.1111/ecc.12120 Ohtsu, 2016, Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer, Presented at ASCO 2016 Annual Meeting, Chicago IL, J Clin Oncol, 34 Hamauchi, 2015, Neutropenia as a predictive factor in patients with metastatic colorectal cancer treated with TAS-102, Presented at ESMO Asia 2015 Congress, Ann Oncol, 26, ix50 Kasi, 2016, Association of chemotherapy induced neutropenia at 1-month mark (CIN-1-month) and overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study, J Clin Oncol, 34 Weingart, 2008, NCCN Task Force report: oral chemotherapy, J Natl Compr Canc Netw, 6, S1 Liu, 1997, Patient preferences for oral versus intravenous palliative chemotherapy, J Clin Oncol, 15, 110, 10.1200/JCO.1997.15.1.110 Borner, 2002, Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer, Eur J Cancer, 38, 349, 10.1016/S0959-8049(01)00371-9 Twelves, 2006, A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer, Ann Oncol, 17, 239, 10.1093/annonc/mdj023 Ruddy, 2009, Patient adherence and persistence with oral anticancer treatment, CA Cancer J Clin, 59, 56, 10.3322/caac.20004 Greer, 2016, A systematic review of adherence to oral antineoplastic therapies, Oncologist, 21, 354, 10.1634/theoncologist.2015-0405 Neuss, 2013, 2013 Updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy, J Oncol Pract, 9, 5s, 10.1200/JOP.2013.000874 Yoshino, 2016, Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors, Cancer Sci, 107, 659, 10.1111/cas.12912 2011 Shinozaki E, Laurent S, Grávalos C, et al. Timing of adverse events (AEs) in the phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC) (abstract 2151). Presented at the European Cancer Congress 2015. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Myeloid Growth Factors. Version 2.2016. Available at: http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf. Accessed: August 3, 2016. Smith, 2015, Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 33, 3199, 10.1200/JCO.2015.62.3488 Kotani, 2016, Safety and efficacy of trifluridine/tipiracil monotherapy in clinical practice for patients with metastatic colorectal cancer: experience at a single institution, Clin Colorectal Cancer, 15, 109, 10.1016/j.clcc.2015.11.005 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cancer- and chemotherapy-induced anemia. Version 2.2017. Available at: http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf. Accessed: February 16, 2017. Schiffer, 2001, Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology, J Clin Oncol, 19, 1519, 10.1200/JCO.2001.19.5.1519 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Antiemesis. Version 2.2016. Available at: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed: August 3, 2016. Basch, 2011, Antiemetics: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 29, 4189, 10.1200/JCO.2010.34.4614 Levine, 2004, Protein-predominant meals inhibit the development of gastric tachyarrhythmia, nausea and the symptoms of motion sickness, Aliment Pharmacol Ther, 19, 583, 10.1111/j.1365-2036.2004.01885.x Levine, 2008, Protein and ginger for the treatment of chemotherapy-induced delayed nausea, J Altern Complement Med, 14, 545, 10.1089/acm.2007.0817 Jednak, 1999, Protein meals reduce nausea and gastric slow wave dysrhythmic activity in first trimester pregnancy, Am J Physiol, 277, G855 Benson, 2004, Recommended guidelines for the treatment of cancer treatment-induced diarrhea, J Clin Oncol, 22, 2918, 10.1200/JCO.2004.04.132 Muehlbauer, 2009, Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea, Clin J Oncol Nurs, 13, 336, 10.1188/09.CJON.336-341 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Palliative Care. Version 1.2016. Available at: https://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf. Accessed: August 3, 2016. Adams, 2009, Putting evidence into practice: evidence-based interventions to prevent and manage anorexia, Clin J Oncol Nurs, 13, 95, 10.1188/09.CJON.95-102 Oncology Nursing Society. Anorexia. Available at: https://www.ons.org/practice-resources/pep/anorexia. Accessed: December 9, 2016. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cancer-Related Fatigue. Version 1.2017. Available at: http://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf. Accessed: February 16, 2017. Mitchell, 2014, Putting evidence into practice: an update of evidence-based interventions for cancer-related fatigue during and following treatment, Clin J Oncol Nurs, 18, 38, 10.1188/14.CJON.S3.38-58